AstraZeneca has rejected Pfzer's latest ofer to buy AstraZeneca. Pfzer says its ofer, which values AstraZeneca at ￡69 billion ($116 bil- lion), is "fnal" and cannot be improved. "We have rejected Pfzer's fnal proposal because it is inadequate and would present signifcant risks for shareholders while also having serious consequences for the company, our employees, and the life sciences sector in the United Kingdom, Sweden, and the Unted States," says AstraZeneca chairman Leif Johansson.
展开▼
